| Market Cap | 212K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -681.26k | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -17.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -45.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -76.00% |
| Recommedations | - | Quick Ratio | - | Shares Outstanding | 35.33M | 52W Low Chg | 50.00% |
| Insider Own | - | ROA | -9,537.98% | Shares Float | 29.21M | Beta | -0.10 |
| Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.00600 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 3,532 | Target Price | - |
| Oper. Margin | - | Earnings Date | - | Volume | 27,710 | Change | 0.00% |
GeneThera, Inc., a biotechnology company, develops molecular assays and therapeutics for the detection and treatment of zoonotic diseases. It offers treatments for zoonotic diseases, such as COVID -19 disease; paratuberculosis (Johne's disease) that is in Stage III clinical phase; mad cow and chronic wasting diseases; and E.coli and salmonella infections, as well as develops vaccine for mycobacterium avium sub paratuberculosis bacteria. The company's Molecular Robotic/AI Platform and Therapeutic strategy is designed to prevent the spread of disease from animals and allow to better control of zoonotic infectious agents. GeneThera, Inc. is based in Westminster, Colorado. GeneThera, Inc., is a subsidiary of Kalos Holdings, Llc.